Clinical Baseline Factors Predict Response to Natalizumab: Their Usefulness in Patient Selection

Alice Laroni,Ilaria Gandoglia,Claudio Solaro,Giuseppe Ribizzi,Tiziana Tassinari,Matteo Pizzorno, Sergio Parodi,Giovanna Baldassarre,Maria Teresa Rilla, Simonetta Venturi,Elisabetta Capello,Maria Pia Sormani,Antonio Uccelli,Giovanni Luigi Mancardi

BMC neurology（2014）

引用 16|浏览7

暂无评分

摘要

Optimal patient selection would improve the risk-benefit ratio of natalizumab treatment for relapsing-remitting multiple sclerosis (RR MS). Clinical features of subjects responding to natalizumab have not been univocally recognized.

查看译文

关键词

Multiple sclerosis,Natalizumab,Neuropharmacology,Clinical neurology

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要